TCR2 raises $125M series B

TCR2 Therapeutics Inc. (Cambridge, Mass.) raised an untranched $125 million series B round led by 6 Dimensions Capital and Curative Ventures and joined by fellow new investors Redmile Group, ArrowMark Partners, Hillhouse Capital, MiraeAsset Financial Group, Syno Capital, Haitong Securities, Lucion Group, Sirona Capital, Alexandria Venture Investments and Leerink Partners affiliates. Existing investors MPM Capital, F2 Ventures and Cathay Fortune Capital Investment also participated (see BioCentury, March 21).

TCR2 is developing T cell receptor fusion constructs (TRuCs), which comprise tumor antigen recognition domains fused to T cell receptors. TRuCs can be programmed to target any surface antigen (see BioCentury, June 23, 2017). ...